Matthew Angel insider trades

Open-market stock purchases and sales by Matthew Angel, CEO and President at Tempest Therapeutics, Inc, from SEC Form 4 filings since Aug 1, 2022.

Track record: 0% of 2 scored buys are up 5% or more since purchase, averaging -76%.

Recent trades

DateStockTradeValue
Mar 24, 2026TPST Tempest Therapeutics, IncBought$500K
Mar 24, 2026TPST Tempest Therapeutics, IncBought$500K
Feb 4, 2026TPST Tempest Therapeutics, IncBought (not open market)—

Companies traded

  • TPST Tempest Therapeutics, Inc: 2 buys, last Mar 24, 2026
  • ERNA Eterna Therapeutics Inc: other filings, last Jan 12, 2023
  • BTX Brooklyn ImmunoTherapeutics, Inc: other filings, last Aug 1, 2022

Get free alerts when Matthew Angel files a new trade →